INBRX-101 is a recombinant human AAT-Fc fusion protein designed to replace the enzyme that is deficient in AATD and offer less frequent dosing than current therapies for the disease, based on ...

The following is a summary of “Higher healthcare cost and utilization before and after diagnosis of AATD in the United States ...

Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational ...

KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD) lung disease In September, after initiating dosing in Cohort 2, the Company amended the protocol for its KB408 Phase 1 SERPENTINE-1 ...

There are an estimated 200,000 individuals living with AATD in the US and Europe with this genetic form of the disease. M-ATT levels were below the limit of detection at baseline, but rose to ...

liver disease, or both, related to AATD. Per the company, approximately 200,000 individuals in the United States and EU have AATD due to the SERPINA1 Z mutation. Current treatments are limited to ...

ReCode’s earlier-stage programs are using SORT LNPs for mRNA-mediated gene addition and gene correction in diseases such as alpha-1 antitrypsin deficiency (AATD), surfactant deficiencies ...

Beam Therapeutics said patient enrollment in the Phase 1/2 trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) is progressing. Site activation globally has continued ...

Additionally, it formed a Clinical Advisory Board (CAB) of lung and liver disease experts to guide the therapy’s clinical development. "Korro secures approvals in Australia to commence AATD ...